

CUMULATIVE INDEX

Volume 28, Numbers 1-4, 1985

- Abortion, septic
 - and endotoxemia, 50
 - shock in, 361
- Abruptio placentae, coagulopathy with, 15-22
 - laboratory tests in, 22
 - management of, 18-21
 - and postpartum hemorrhage, 21
- Acidosis, in endotoxic shock, 358, 359
- ACTH, 623
 - serum levels of
 - in anorexia nervosa, 624, 625
 - in obesity, 624
- Acyclovir, in herpes genitalis, 159, 161
- Adenofibromas of ovary, 789
- Adolescence. *See* Puberty
- Adrenal hormones, weight changes affecting, 623-625
 - in obesity, 624
 - in starvation of malnutrition, 625-625
- Age, and postoperative venous thrombosis, 634
- Airway emergencies, in anesthesia, 393-395
- Alcohol injections, in pruritus vulvae, 132
- Aldose reductase inhibitors, effects in diabetes, 537
- Aldosterone, 623
- Allergic dermatitis of vulva, 127, 179
- Amenorrhea
 - in anorexia nervosa, 589, 600-601, 622
 - in athletes, 577, 664-669
 - and bone mineral density, 671
 - diagnostic evaluation in, 667-668
 - dietary factors in, 665-666
 - hormone alterations in, 666-667
 - stress factors in, 665
 - treatment of, 668-669
 - weight loss in, 664-665
 - in bulimia, 608
 - in dancers, 577, 594, 665
 - in obesity, 621
 - in weight loss, 638
- Amino acid levels, in pregnancy, 459
- Aminoglycosides, nephrotoxicity of, 410
- Amnioinfusion, saline, in fetal distress, 778
- Amniotic fluid
 - cultures after rupture of membrane, 698-699
 - embolism, 32-35
- Anaphylactoid reactions, to anesthetic agents, 401
- Androblastomas, 792, 838
- Androgens
 - metabolism affected by weight loss, 622-623
 - production in women, 619-620
 - serum levels in obesity, 621, 648-650
- Androstenediol glucuronide, 620
 - serum levels in obesity, 621
- Androstenedione
 - metabolism affected by weight loss, 622-623
 - production in women, 619, 623
 - serum levels in obesity, 621
- Anemia
 - and postpartum infections, 700
 - in pyelonephritis, 272-273
- Anesthesia
 - airway and ventilation emergencies in, 393-395
 - anaphylactoid reactions to agents in, 401
 - aspiration of gastric contents in, 395-396
 - prophylactic measures in, 396
 - bronchospasm in, 402
 - cardiac arrest in, 392-393
 - for cesarean section, 722-733
 - and emergencies during laparoscopy, 402
 - malignant hyperthermia in, 396-398
 - muscle relaxants in, emergencies from, 398-399
 - regional
 - emergencies from, 399-401
 - in trial of labor after prior cesarean, 738-739
- Angiography
 - pulmonary, in pulmonary embolism, 438
 - renal, postpartum, 302
- Anorexia nervosa, 588-596, 598-606, 615-616
 - amenorrhea in, 589, 600-601, 622
 - atypical symptoms in, 602
 - behavior therapy in, 595, 604, 605-606
 - bulimic type of, 602
 - carbohydrate metabolism in, 630
 - clinical features of, 589-590, 601
 - compared to starvation, 589, 592, 601
 - cortisol metabolism in, 624-625
 - drug therapy in, 595, 604
 - early detection of, 611-612
 - etiology of, 599-601
 - fertility in, 595
 - gender distribution of, 588, 602-603
 - gonadotropin secretion in, 634

- groups at risk for, 594
 growth hormone levels in, 626-627
 hospitalization in, 604
 insulin levels in, 630
 management of, 595-596, 603-606
 nutritional support in, 604-605
 prevalence of, 588, 602, 632
 psychologic changes in, 594-595, 603
 restrictor type of, 602
 spontaneous recovery from, 603-604
 steroid hormone levels in, 622-623
 thyroid function in, 618, 624
- Anovulation, in obesity, 655-658
- Antacids, before cesarean section, 725
- Antenatal testing, and fetal outcome in diabetic pregnancy, 491-492, 516-525
- Antibiotics
 in bacteriuria of pregnancy, 267-268
 colitis from, 410-411
 in cystitis of pregnancy, 269-270
 in endotoxic shock, 359
 corticosteroids with, 357
 in infections after cesarean section, 702-705
 new beta-lactam agents, 411-412
 in pelvic inflammatory disease, 408-412
 prophylactic use in cesarean section, 705-707
 in extraperitoneal operation, 714
 in pyelonephritis of pregnancy, 276
- Anticoagulants, oral
 in postoperative venous thromboembolism, 441
 in prophylaxis of venous thrombosis, 444
- Antidepressants
 in anorexia nervosa, 604
 in bulimia, 611
- Antidiuretic hormone secretion, in pregnancy, 263-264, 282
- α_2 -Antiplasmin, 12
 deficiency in pregnancy, 67
- Antithrombin III, 10-11
 deficiency in pregnancy, 57-58
 treatment of, 58
 serum levels of
 oral contraceptives affecting, 78
 in preeclampsia, 39
- Anxiety
 and amenorrhea in athletes, 665
 and bulimia, 609
- Aortocaval compression, in supine position in pregnancy, 723-724, 726
- Appendicitis, differential diagnosis of, 379
- Aprotinin, in abruptio placentae with coagulopathy, 20-21
- Arrhenoblastoma, 792, 838
- Asphyxia, perinatal. *See* Fetus, distressed
- Aspiration
 of gastric contents in anesthesia, 395-396
 and pneumonitis during labor, 724-725
- Aspirin, in endotoxic shock, 357
- Athletes, amenorrhea in, 577, 664-669
- Azathioprine, in pregnancy, in renal transplant patients, 344-345
- Bacteriuria in pregnancy, 266-268
 postpartum evaluation in, 303
 and pyelonephritis, 266, 270
 reinfection in, 268
 relapse in, 268
- Bartholin duct cysts, 134-135, 139
- Basal-cell nevus syndrome, ovarian fibromas in, 838
- Basement membrane changes in tissues, in diabetes, 537
- BCG vaccine, in ovarian cancer, 856-857
- Behavior therapy
 in anorexia nervosa, 595, 604, 605-606
 in bulimia, 609-611
- Bernard-Soulier syndrome, 4
- Biopsy, renal
 in acute renal failure in pregnancy, 295, 308
 in postpartum period, 302
- Bladder
 cystitis in pregnancy, 269-270
 morphologic changes in pregnancy, 254
- Blood flow
 abnormalities in diabetes, 538
 renal
 postpartum, 299
 in preeclampsia, 281-282
 in pregnancy, 257
- Blood gas studies
 in cancer patients, 418
 in pulmonary embolism, 438
- Blood transfusions
 in abruptio placentae, 18-19
 in hemorrhagic shock, 385
 renal failure from, 291
- Body composition, in adolescence, 576
- Body image
 in anorexia nervosa, 601
 and weight control, 640
- Body weight disorders. *See* Weight
- Bone mass, premenopausal, weight affecting, 670-679
- Breech presentation, cesarean section in, 693
 in preterm birth, 752-754
- Brenner tumor of ovary, 789
- Bronchospasm in anesthesia, 402
- Bulimia, 588-596, 606-612
 and anorexia nervosa, 602
 atypical patterns in, 607
 behavior therapy in, 609-611
 binge eating in, 607, 609
 clinical features of, 590, 606-607
 dental problems in, 590, 603, 608
 drug therapy in, 611
 early detection of, 611-612

CUMULATIVE INDEX

- etiology of, 599-601
 gender distribution of, 588, 608
 incidence of, 588, 608
 nervosa, 588-589, 606
 neurologic disorders with, 601, 608
 physical complications of, 608
 psychologic theories of, 608-609
 purging in, 602, 607, 609
 treatment of, 609-611
- Bulimic anorexia, 602
- Bupivacaine, for epidural block in cesarean section, 728-729, 732
- Calcium
 dietary, 674
 metabolism of
 estrogen affecting, 674
 in pregnancy, in renal transplant patients, 343
 serum levels in cancer patients, 416-417
- Calculi, renal, in pregnancy, 271, 324-337
 clinical experience with, 328-335
 differential diagnosis of, 379
 etiology of, 326
 incidence of, 324
 radiographic studies in, 327-328
 symptoms of, 326
 treatment of, 335-336
- Calf compression system, in prophylaxis of venous thrombosis, 444
- Cancer, gynecologic, 414-430
 and complications during surgery, 420-421
 disseminated intravascular coagulation in, 422
 ileus in, 426-427
 infected wounds in, 428-429
 peritonitis in, 427-428
 rapid blood tests in, 421-422
 shock lung in, 423-426
 wound dehiscence in, 428
 drug monitoring in, 429
 fluid and electrolyte replacement in, 415-419
 ovarian, 785-872. *See also* Ovaries, tumors of
 parenteral nutrition in, 419-420
 and septic shock after chemotherapy, 361-362
 venous thrombosis in, 435
 of vulva. *See* Vulva, carcinoma of
- Carbohydrates
 dietary, metabolic responses to, 628
 metabolism of
 in anorexia nervosa, 630
 placental, 474-476
 in pregnancy, 458-459
- Carbon dioxide laser, in vulvar disease, 220-228
- Carcinoma. *See* Cancer, gynecologic
- Cardiopulmonary resuscitation, in operating room, 393
- Catecholamine activity, in obesity, 653-654
- Cefamandole, in infection after cesarean section, 703
- Cefoperazone, in infection after cesarean section, 703
- Cefotaxime
 in infection after cesarean section, 703
 in pelvic inflammatory disease, 411
- Cefoxitin
 in infection after cesarean section, 703
 in pelvic inflammatory disease, 409
- Cervicitis, vulvodynia in, 129
- Cesarean section, 689-779
 anesthesia for, 722-733
 and aortocaval compression in supine position, 723-724, 726
 and aspiration pneumonia, 724-725
 dose requirements in, 725-726
 epidural block in, 732-733
 fetal considerations in, 726-730
 general anesthesia in, 729, 730-731
 hyperventilation in, 727-728
 hypotension from, 726-727
 induction-delivery interval in, 729-730
 local anesthetics in, 728-729
 maternal considerations in, 723-726
 muscle relaxants in, 730
 oxygenation in, 725, 728
 subarachnoid block in, 731-732
 uterine incision-delivery interval in, 729-730
- in breech presentation, 693
 in preterm delivery, 752-754
 in diabetic pregnancy, insulin requirements in, 503, 504
 in dystocia, 592, 745-748
 and vaginal delivery in later pregnancy, 740-741
 advantages of, 718-719
 antibiotics in, 714
 bladder management in, 714
 combined approach in, 715-716
 contraindications to, 717
 drains in, 714
 historic aspects of, 711-713
 incision in, 714
 morbidity of, 716-717
 paravesical, 714-715
 selection of patients for, 717-718
 supravesical, 715
 ureter in, 714
- in fetal distress, 693, 748-750, 773
 financial aspects of, 742, 767
 in gestational diabetes, 513
 indications for, 741, 745-748
 infection after, 697-707, 766-767
 after rupture of membranes, 698-699
 causes of antibiotic failure in, 704-705
 clinical features of, 698
 differential diagnosis of, 702
 duration of labor affecting, 698

- incidence of, 697-698
- from internal fetal monitoring, 699
- laboratory evaluation of, 701-702
- microbiology of, 700-701
- risk factors for, 698-700
- treatment of, 702-705
- and malpractice issue, 693-694
- maternal morbidity in, 765-767
- maternal mortality in, 763-764
- and postoperative and analgesia with narcotics, 733
- for preterm deliveries, 752-758
 - benefits of, 756
 - in breech delivery, 752-754
 - hazards of, 756
 - incisions in, 757-758
 - and intraventricular hemorrhage prevention, 755-756
 - in twin deliveries, 755
 - in vertex delivery, 755
- prophylactic antibiotics in, 705-707
- psychologic effects of, 767
- in renal transplant patients, 346
- repeat, 692
 - financial considerations in, 742
 - review questions on, 783-784
 - trends in frequency of, 691-695
- vaginal birth after, 693, 735-742
 - and fear of uterine rupture, 736
 - and trial of labor, 736-742. *See also* Labor, trial of, after prior cesarean
- Chemotherapy
 - in ovarian cancer, 807-810, 820, 847-848
 - and septic shock, 361-362
- Chlamydia trachomatis*, antibiotics affecting, 409
- Chlorporocaine, for epidural block at cesarean section, 728-729, 732
- Chlorpromazine
 - in hemorrhagic shock, 386
 - in septic shock, 360
- Choriocarcinoma of ovary, 794, 826-827
- Chorionic gonadotropin assay
 - in ectopic pregnancy, 367
 - in ovarian tumors, 828
- Chorionic somatomammotropin, 461
- Cimetidine, before cesarean section, 725
- Clindamycin
 - in infection after cesarean section, 703
 - in pelvic inflammatory disease, 409
- Clomiphene citrate, for ovulation induction
 - in athletic amenorrhea, 668
 - in obesity, 657
 - in slender women, 642
- Clomipramine, in anorexia nervosa, 604
- Coagulation
 - cascade in, 7-9
 - cofactors in, 6-7
 - current concepts of, 3-13
 - disseminated intravascular
 - and abruptio placentae, 17-21
 - in cancer patients, 422
 - in endotoxic shock, 356
 - in fetal death syndrome, 25
 - in septic shock, 48-49
 - enzymes in, 5-6
 - and oral contraception, 73-81
 - in pregnancy, 16, 49-50
 - primary, 3-4
 - rapid tests of, 421-422
 - regulation of, 10-13
 - and thrombogenesis, 434-435
- Coagulopathy in pregnancy
 - and abruptio placentae, 15-22
 - and amniotic fluid embolism, 34
 - management of, 35
 - and fetal death syndrome, 24-30
 - disseminated intravascular coagulation in, 25
 - fibrinolysis in, 26-27
 - laboratory studies in, 27-28
 - management of, 28-29
- hereditary, 53-68
 - prenatal diagnosis of, 67-68
 - screening tests in, 54
 - and preeclampsia, 37-44
 - review questions on, 120
 - and septic shock, 46-51
- Colitis, antibiotic-associated, 410-411
- Colpotomy, in ectopic pregnancy, 369-370
- Computed tomography, renal postpartum, 302
- Condyloma acuminatum, 142-48
 - clinical features of, 144
 - and concomitant sexually transmitted diseases, 145
 - etiology of, 142-143
 - immune response in, 145-146
 - incubation period in, 143-144
 - malignancy related to, 146
 - predisposing factors in, 144-145
 - treatment of, 146-148
- Congenital malformations, in infants of diabetic mothers, 486-494, 554, 557-558, 559
- Contraception
 - in athletic amenorrhea, 668
 - counseling in renal transplant patients, 348
 - in diabetes, 561-565
 - oral
 - and coagulation, 73-81
 - and ovarian cancer risk, 797
- Contraction stress tests, uterine, fetal heart rate in, 517-518, 522-523
- Convulsions, in regional anesthesia, 399-400
- Coronary artery disease in diabetes, and pregnancy outcome, 533-534
- Corticosteroid therapy
 - in endotoxic shock, 360
 - antibiotics with, 357
 - in pregnancy

- in immunologic thrombocytopenic purpura, 93
 - in lupus nephritis, 319-321
 - in renal transplant patients, 344
- vulvar burning from, 130
- Cortisol, 623
 - serum levels of
 - in anorexia nervosa, 624-625
 - in obesity, 624
- Corynebacterium parvum* therapy, in ovarian cancer, 857, 865
- Counseling
 - contraceptive, for renal transplant patients, 348
 - genetic, in diabetic pregnancy, 493, 555
 - prepregnancy, in diabetes, 553-561
- Creatinine clearance
 - postpartum evaluation of, 300
 - in pregnancy, 258-259
 - in pyelonephritis, 272
 - tests for, 280
- Cricothyroidotomy, in anesthetic emergencies, 394
- Cryotherapy, in condyloma acuminata, 147-148
- Crystalloid solutions, in hemorrhagic shock, 384
- Culdocentesis, in ectopic pregnancy, 366
- Curare, anesthetic emergencies from, 398-399
- Cushing's syndrome, obesity in, 621
- Cyclophosphamide in pregnancy in renal transplant patients, 345
- Cyclosporin A in pregnancy, in renal transplant patients, 345-346
- Cyproheptadine, in anorexia nervosa, 604
- Cyst
 - Bartholin, 134-135, 139
 - hymenal, in newborn, 139
- Cystadenoma of ovary, 789
- Cystitis in pregnancy, 269-270
- Dancers
 - amenorrhea in, 577, 594, 665
 - anorexia nervosa in, 594
- Dantrolene, in malignant hyperthermia, 398
- Dehydroepiandrosterone production, in women, 619, 623
 - in anorexia nervosa, 622
 - in obesity, 621
- Delivery
 - diabetes management in, 502-504
 - in diabetic retinopathy, 549
 - in fetal thrombocytopenia, 96-98
 - in gestational diabetes, 513-514
 - preterm. *See* Prematurity
- Depression, bulimia in, 608
- Dermatitis of vulva
 - allergic, 127, 179
 - seborrheic, 128-129
- Dermatophyte infections of vulva, 129
- Dexamethasone test
 - in anorexia nervosa, 625
 - in obesity, 624, 655
- Dextran solutions
 - in hemorrhagic shock, 384
 - in prophylaxis of venous thrombosis, 444
- Diabetes mellitus
 - contraception in, 561-565
 - combined oral contraceptives in, 562-563
 - intrauterine device in, 563-564
 - mechanical methods in, 564
 - and natural family planning, 565
 - progestogen-only preparations in, 564-565
 - sterilization in, 565
 - vasectomy in, 565
 - gestational, 467-470, 507-515
 - delivery in, 513-514
 - detection of, 508-510
 - diet in, 511
 - fetoplacental function testing in, 512-513
 - insulin therapy in, 511-512
 - monitoring of glucose levels in, 510-511
 - postpartum follow-up in, 514
 - treatment of, 510-514
 - infertility in, 556
 - microangiopathy in, mechanisms in, 536-539
 - and obesity, 629
 - in pregnancy, 455-567
 - antepartum testing in, 516-525
 - biochemical, 517
 - biophysical, 517-519
 - contraction stress test in, 517-518, 522-523
 - diagnostic predictiveness of, 519-523
 - estriol in, 517, 519-522
 - fetal biophysical profile in, 519, 523
 - fetal movements in, 528-529
 - nonstress test in, 518, 522-523
 - placental lactogen in, 517
 - and congenital malformations in fetus, 486-494, 554, 557-558, 559
 - prenatal detection of, 491-492
 - and genetic counseling, 493, 555
 - gestational diabetes, 467-470, 507-515
 - importance of glucose regulation in, 523-525
 - insulin administration in, 496-504
 - continuous subcutaneous infusions in, 500-502
 - during labor and delivery, 502-504
 - multiple-injection regimens in, 497-498
 - new insulins and antibodies in, 498-499
 - metabolism in, 462-471
 - monitoring of glucose levels in, 499-500
 - in gestational diabetes, 510-511
 - nephropathy in, 308, 528-534
 - diagnosis of, 529
 - and ischemic heart disease, 533-534
 - management of, 532
 - maternal complications of, 531
 - pathogenesis of, 529-531
 - perinatal outcome in, 532-533

- in transplantation and dialysis patients, 532
 - placenta in, 463-465
 - retinopathy in, 546-549
 - review questions, 567
 - type I diabetes, 465
 - type II diabetes, 465-466
- pregnancy counseling in, 553-561
 - and advice against pregnancy, 556
 - aims of, 554-556
 - effects on diabetic control, 557
 - motivation in, 556-557
 - and outcome of pregnancy, 557-558
 - problems in, 560-561
- retinopathy in, 539-546
 - background, 539-540
 - in pregnancy, 547
 - microaneurysms in, 539
 - neovascularization in, 540-546
 - photocoagulation in, 540, 544-545, 547, 548
 - in pregnancy, 546-549
 - management of, 548-549
 - proliferative, 540-546
 - in pregnancy, 547-548
 - vitrectomy in, 546
- somatomedin activity in, 625
- Dialysis
 - in acute renal failure in pregnancy, 295
 - in diabetic nephropathy in pregnancy, 531-532
 - in lupus nephropathy in pregnancy, 321
- Diet. *See* Nutrition
- Digitalis
 - in hemorrhagic shock, 385
 - in septic shock, 361
- Dihydrotestosterone
 - metabolism affected by weight loss, 622-623
 - production in women, 619
 - secretion in obesity, 621
- Dinitrochlorobenzene (DNCB), in condyloma acuminatum, 148
- Diuretic abuse, in bulimia, 607
- Dobutamine, in hemorrhagic shock, 386
- Dopamine therapy
 - in endotoxic shock, 357, 360-361
 - in hemorrhagic shock, 385-386
- Doxycycline, in pelvic inflammatory disease, 409
- Dwarfism, Laron, 625
- Dysgerminomas, 793, 824-825
 - torsion of, 379
- Dyspareunia, in vestibular gland inflammation, 129, 136, 227
- Dystocia, cesarean section in, 692, 745-748
 - and vaginal delivery in later pregnancy, 740-741
- Eating disorders. *See also* Anorexia nervosa; Bulimia
 - endocrine changes in, 590
 - hypothalamic dysfunction in, 590-594, 600-601
- Eclampsia, coagulation system in, 37
- Ectopic pregnancy, 365-374
 - chorionic gonadotropin assay in, 367
 - clinical features of, 366
 - colpotomy in, 369
 - cornual resection in, 369
 - differential diagnosis of, 378-379
 - fimbrial evacuation in, 371-372
 - Gepfert procedure in, 372
 - laparoscopy in, 368
 - midsegment anastomosis in, 372
 - ovariectomy in, 370
 - preservation of fertility in, 372-373
 - Rh immunoglobulin in, 373
 - risk factors for, 365-366
 - salpingectomy in, 369
 - salpingostomy in, 370-371
 - salpingotomy in, 371
 - tubouterine implantation in, 372
 - ultrasonography in, 367-368
- Edema, pulmonary
 - in pyelonephritis, 274-275
 - in shock lung syndrome, 424
- Electrocardiography
 - in pulmonary embolism, 438
 - in septic shock, 359
- Electroencephalography, in bulimia, 601, 608
- Electrosurgery, in condyloma acuminatum, 148
- Embolectomy, pulmonary, 442
- Embolism
 - amniotic fluid, 32-35
 - pulmonary
 - diagnosis of, 108-109, 437-438
 - postoperative, 432
 - treatment of, 115
- Embryonal carcinoma, ovarian, 794, 826
- Endocrine function. *See* Hormones
- Endodermal sinus tumors, 793, 825
- Endometritis, after cesarean section, 697. *See also* Cesarean section, infection after
- Endorphin levels, in obesity, 653
- Endothelial cells, and coagulation regulation, 12
- Endotoxins
 - placental lesions from, 50
 - and septic shock, 46-51
 - in gynecologic patients, 355-363
- Epidermodysplasia verruciformis, and cutaneous malignancy, 146
- Epidural anesthesia
 - in cesarean section, 732-733
 - in trial of labor after prior cesarean, 738-739
- Epithelial ovarian tumors, 789-792
- Estril, in test of fetal status, 517, 519-522
- Estrogen
 - biosynthesis of, 581
 - and calcium metabolism, 674
 - extraglandular production affected by body weight, 580-585
 - metabolism affected by weight loss, 636

- production in women, 619
 in anorexia nervosa, 596, 622
 in obesity, 622, 646-648
 and somatomedin synthesis, 625
 therapy with
 in athletic amenorrhea, 668
 and postoperative venous thrombosis, 436
 in premenopausal osteopenia, 678
- Exercise
 and amenorrhea in athletes, 664-669
 and body fat, 577
 and oral contraceptive use, 80
 as purging strategy in bulimia, 607
- Factor II. *See* Prothrombin
- Factor V, 6
 deficiency in pregnancy, 63
 serum levels in abruptio placentae, 16
- Factor VII, 5
 activation of, 8
 deficiency in pregnancy, 62-63
 treatment of, 63
 oral contraceptives affecting levels of, 76
- Factor VIII, 6-7, 55
 serum levels in abruptio placentae, 16
- Factor IX, 5
 activation of, 7-8
 deficiency in pregnancy, 60-61
 treatment of, 61
- Factor X, 5
 activation of, 8
 deficiency in pregnancy, 63-64
 oral contraceptives affecting levels of, 76
- Factor XI
 activation of, 7
 deficiency in pregnancy, 61-62
 treatment of, 62
- Factor XII
 activation of, 7
 deficiency in pregnancy, 62
- Factor XIII, 6
 deficiency in pregnancy, 64-65
 treatment of, 65
- Fallopian tubes
 pregnancy in. *See* Ectopic pregnancy
 torsion of, 376-377
- Family role in eating disorders, 600
- Fat
 in body
 in adolescence, 576
 and extraglandular estrogen production, 580-585
 and hormonal changes, 577-578
 and menarche, 621, 633
 and physical activity, 577
 dietary, metabolic responses to, 628
 metabolism in pregnancy, 461
- Fertility
 disorders in. *See* Infertility
 preservation of, in ectopic pregnancy, 372-373
- Fetoplacental function testing, in gestational diabetes, 512-513
- α -Fetoprotein levels, in ovarian tumors, 828
- Fetus
 biophysical profile of, 519, 523
 death of
 in coagulopathy, 24-30
 in multiple gestation, 29-30
 distressed
 in antepartum period, 775-776
 cesarean section in, 693, 748-750, 776
 diagnosis of, 748-750
 identification of, 771-775
 neonatal sequelae of, 770-771
 nonsurgical management of, 777
 in preterm gestations, 776-777
 prevention of, 750
 saline amnioinfusion in, 778
 tocolytics in, 777-778
 glucose metabolism in, 476-478
 oxidation in, 478
 uptake in, 476
 utilization in, 477-478
 glucose release in, 480-481
 glycogen formation in, 480-481
 heart rate in, 748-750, 772-774
 baseline, 773
 decelerations in, 773-774
 sinusoidal pattern in, 774
 variability of, 773
 insulin activity in, 470, 479
 lactate metabolism in, 478-479
 malformations in diabetic pregnancies, 486-494, 554, 557-558, 559
 metabolism affected by insulin, 480
 monitoring of, 748-750
 in diabetic pregnancy, 516-525
 in nephropathy, 531
 and infection from internal monitors, 699
 movements of, surveillance of, 518-519
 pancreatic development in, 479
 risk during trial of labor, 741-742
 scalp sampling of, 750, 774-775
- Fever
 after cesarean section, 697
 in malignant hyperthermia, 396-398
 in pyelonephritis, 271
 in septic shock, 358
- Fibrin gel formation, 9
- Fibrinogen
 abnormalities in pregnancy, 65-66
 conversion to fibrin, 9
 serum levels of
 in abruptio placentae, 16
 in preeclampsia, 39

- uptake test for thrombosis detection, 110-111
- Fibrinolysis, 12
- in abruptio placentae, 17-18
 - management of, 19-21
 - and fetal death syndrome, 26-27
 - oral contraceptives affecting, 74, 79-80
 - and venous thrombogenesis, 434
- Fibromas of ovary, 842
- Fluid replacement
- in acute renal failure in pregnancy, 294
 - in cancer patients, 415-419
 - in endotoxic shock, 359
 - in hemorrhagic shock, 383-384
- Fluid volume
- postpartum, 299
 - in pregnancy, 263
 - in acute renal failure, 290
 - in preeclampsia, 282
- Follicle-stimulating hormone
- and estrogen production, 619
 - serum levels of
 - in malnutrition, 622
 - in obesity, 647, 650
 - weight loss affecting, 634-636
- Gelfoam, for embolization of hypogastric arteries in hemorrhage, 388-389
- Genetics
- and counseling in diabetic pregnancy, 493, 555
 - and obesity, 658
 - and ovarian cancer, 798
- Gentamicin
- in infection after cesarean section, 703
 - in pelvic inflammatory disease, 410
- Germ-cell ovarian tumors, 793-794, 824-834
- mixed, 794, 827
- Glanzmann's thrombasthenia, 4
- Glomerular filtration rate
- postpartum, 299
 - in pregnancy, 257-258
 - in preeclampsia, 282
 - in renal transplant patients, 342
- Glucagon, 627-628
- metabolism in malnutrition, 629-630
 - serum levels in anorexia nervosa, 630
- Glucocorticoid secretion, weight changes affecting, 623-625
- Glucose
- fetal metabolism of, 476-478
 - intolerance during pregnancy, 467, 507. *See also*
 - Diabetes mellitus, gestational
 - metabolism in obesity, 628-629
 - monitoring of
 - in diabetic pregnancy, 499-500
 - in gestational diabetes, 510-511
 - neonatal metabolism of, 481-483
 - placental metabolism of, 474-476
 - regulation in diabetic pregnancy, importance of, 523-525
 - release in fetus, 480-481
 - serum levels of
 - in anorexia nervosa, 630
 - in endotoxic shock, 356
 - in pregnancy, 458-459, 496
 - supply to pregnant uterus, 474
 - tolerance test for gestational diabetes, 509-510
- Glycogen formation in fetus, 480-481
- Glycosuria in pregnancy, 261-262
- Glycosylation in tissues, hyperglycemia affecting, 537-538
- Gonadal dysgenesis, and luteinizing hormone secretion during sleep, 574
- Gonadotropin
- chorionic, assay of
 - in ectopic pregnancy, 367
 - in ovarian tumors, 828
 - for ovulation induction in obesity, 657
 - releasing hormone secretion, 620
 - in eating disorders, 590, 593-594
 - serum levels of
 - in anorexia nervosa, 634
 - in obesity, 647, 650-651
- Gonorrhea, antibiotics in, 409
- Granulosa-cell tumors of ovary, 792, 839-841
- Growth hormone
- releasing factor, 625-626
 - weight changes affecting, 625-627
 - in obesity, 626
 - in starvation or malnutrition, 626-627
- Growth retardation, in fetuses of diabetic mothers, 489-490
- Gynandroblastomas, 844-845
- Hageman factor. *See* Factor XII
- Heart
- cardiac arrest during anesthesia, 392-393
 - ischemic disease in diabetes, and pregnancy outcome, 533-534
- Heart rate, fetal, 748-750, 772-774
- in uterine contraction stress tests, 517-518, 522-523
- Hemoglobin A₁ levels in pregnancy, 557
- and fetal malformations, 490-491, 554
- Hemolytic uremic syndrome in pregnancy, 101-105
- Hemophilia A, 6
- in pregnancy, 58-60
 - treatment of, 60
- Hemophilia B, in pregnancy, 60-61
- Hemorrhage
- and acute renal failure in pregnancy, 290
 - intraventricular, in preterm infants, cesarean section affecting, 755-756
 - postpartum, in abruptio placentae, 21
- Hemorrhagic shock, 381-389

CUMULATIVE INDEX

- hemostasis. *See* Coagulation
- Heparin therapy
 in disseminated intravascular coagulation with retained dead fetus, 29
 in postoperative venous thromboembolism, 440-441
 in prophylaxis of venous thrombosis, 443-444
 in septic shock, 361
 in thromboembolic disease in pregnancy, 111-116
- Herpes genitalis, 152-161
 carbon dioxide laser in, 227-228
 clinical features of, 153
 epidemiology of, 156-157
 initial infection in, 153-154
 neonatal, 157-158
 prevention and treatment of, 158-161
 recurrent, 154-156
 vaccines in prevention of, 158, 164-176
 based on glycoprotein D, 169-171
 classification of, 166
 feasibility of, 164-166
 inactivated virus in, 166-168
 Marek's disease virus in, 171-172
 modified live virus in, 171-175
 subunit, 168-169
 vaccinia virus in, 170-171
 varicella-zoster virus in, 172
 virulence of virus in, 172-175
- Herpes zoster, vulva in, 130
- Hexoprenaline, in fetal distress, 778
- Hirsutism, in obesity, 621
- Hormones
 abnormalities in obese women, 646-655
 body fat affecting, 577-578, 580-585
 changes in eating disorders, 590
 exercise affecting, 666-667
 weight change affecting, 615-630
- Hydrourerter of pregnancy, 249-253
- Hymen
 cysts in newborn, 139
 lacerations of, 138
- Hypertension in pregnancy
 coagulation system in, 37-44
 postpartum evaluation in, 303-304
 and preeclampsia, 279-285
 in renal transplant patients, 342
- Hyperthecosis in obesity, 655-656
- Hyperthermia, malignant, 396-398
- Hyperventilation, and anesthesia for cesarean section, 727-728
- Hypogastric artery
 embolization of, in hemorrhage, 388-389
 ligation of, in hemorrhage, 387
- Hypotension
 in acute renal failure in pregnancy, 290
 anesthesia-induced, 726-727
 in septic shock, 358
 supine, in pregnancy, 723-724
- Hypothalamic dysfunction
 in eating disorders, 590-594, 600-601
 in obese males, 654
 and premenopausal osteopenia, 670-679
 in weight loss, 634-636
- Hypovolemia, in acute renal failure in pregnancy, 290
- Hypoxia, perinatal. *See* Fetus, distressed
- Hysterectomy
 hemorrhage control in, 387
 in septic shock, 361
- Ileus, postoperative, in cancer patients, 426-427
- Immobilization, and postoperative venous thrombosis, 436
- Immune response mechanisms
 in cancer, 854-856
 in condyloma acuminata, 145-146
- Immunologic thrombocytopenic purpura in pregnancy, 84-99
- Immunoscintigraphy, in ovarian cancer detection, 860-861
- Immunosuppressive therapy
 in pregnancy
 in lupus nephropathy, 320
 in renal transplant patients, 344-346
 and septic shock, 361-363
- Immunotherapy
 in condyloma acuminata, 148
 in ovarian cancer, 856-857, 861-867
- Infection
 in acute renal failure in pregnancy, 294
 after cesarean section, 697-707, 766-767
 and ectopic pregnancy, 365
 and septic shock, 355-363
 urinary tract, in pregnancy, 266-277
 postpartum evaluation in, 303
 in renal transplant patients, 341
 of wounds in cancer surgery, 428-429
- Infertility
 in anorexia nervosa, 595
 in diabetes, 556
 in obesity, 656
 and ovulation induction. *See* Ovulation induction and weight control practice, 632-642
- Inositol in tissue, hyperglycemia affecting, 537
- Insulin
 activity in pregnancy, 458, 461-462
 administration in diabetic pregnancy, 496-504
 in gestational diabetes, 511-512
 in labor and delivery, 502-504
 prophylactic, 512
 affecting fetal metabolism, 480
 binding to receptors, 627
 role in fetal life, 470
 secretion in fetus, 479
 serum levels of

CUMULATIVE INDEX

- in anorexia nervosa, 630
 - in malnutrition, 629
 - in obesity, 628-629, 651-653
- and somatomedin activity, 625
- Insulinlike hormones, 538
- Interferon therapy, in ovarian cancer, 857, 865-867
- Intubation, endotracheal
 - complications from, 393-394
 - and Sellick's maneuver, 395, 396
- Iodine metabolism, and thyroid hormone synthesis, 616
- Isoproterenol, in septic shock, 360

- Kallikrein, 7
- Kidney
 - acute failure in pregnancy, 288-296, 305-308
 - in acute tubular necrosis, 291, 305
 - biopsy of kidney in, 295, 308
 - in cortical renal necrosis, 291, 306
 - diagnosis of, 292-293
 - dialysis in, 295
 - fluid replacement in, 294
 - hyperkalemia in, 294
 - hyponatremia in, 294
 - idiopathic postpartum, 292, 307
 - infection in, 294
 - nutrition in, 294
 - postrenal, 291-292
 - prerenal, 290-291
 - renal, 291
 - aminoglycoside nephrotoxicity, 410
 - chronic disease of, and pregnancy outcome, 285-287
 - diabetic nephropathy in pregnancy, 308, 528-534
 - in endotoxic shock, 356
 - morphologic changes in pregnancy, 249-253
 - physiology in pregnancy, 257-264
 - postpartum evaluation of function, 298-308
 - angiography in, 302
 - biopsy in, 302
 - computed tomography in, 302
 - glomerular function in, 300
 - intravenous pyelography in, 301
 - nuclear magnetic resonance in, 302
 - tubular function in, 300-301
 - ultrasonography in, 301
 - transplantation of
 - during pregnancy, 349
 - pregnancy after, 317, 339-349
 - calcium metabolism in, 343
 - and contraceptive counseling, 348
 - corticosteroids in, 344
 - delivery in, 346
 - effects on offspring, 347-348
 - hypertension in, 342
 - immunosuppressive therapy in, 344-346
 - infections in, 341-342
 - and prematurity, 342
 - rejection of graft in, 343

- Labor
 - diabetes management in, 502-504
 - duration of, and infection after cesarean section, 698
 - trial of, after prior cesarean, 736-742
 - after multiple prior cesareans, 739-740
 - epidural anesthesia in, 738-739
 - hospital requirements for, 740
 - outcome of, 740
 - oxytocin use in, 737-738
 - in postterm pregnancy, 739
 - risks in, 741-742

- Lactate
 - fetal uptake and metabolism of, 478-479
 - placental production of, 476
- Lactic acidosis, in cancer patients, 417
- Lactic dehydrogenase levels, in ovarian dysgerminomas, 828
- Lactogen, placental, 461
 - in test of fetal status, 517
- Laparoscopy
 - in ectopic pregnancy, 368
 - emergencies in, 402
- Laparotomy in ovarian cancer, 800-805
 - second-look in, 816-820
 - third-look in, 820
- Laron dwarfism, 625
- Laser therapy, in vulvar disease, 220-228
 - in condyloma acuminata, 148
- Laxative abuse, in bulimia, 607
- Lichen sclerosis of vulva, 128, 181-185
 - carbon dioxide laser in, 226
 - and carcinoma development, 183-184
 - treatment of, 184-185
- Lichen simplex chronicus of vulva, 127-128
- Lidocaine, for epidural block at cesarean section, 728-729, 732
- Lipid metabolism, hormonal control of, 628
- Lipoprotein lipase activity, during weight loss, 659
- Lithium therapy, in anorexia nervosa, 604
- Liver
 - in endotoxic shock, 356
 - fatty, in pregnancy, 306

- Lung
 - acute injury in septic shock, 49
 - disorders of cancer patients, 418
 - dysfunction in pyelonephritis, 273-276
 - in endotoxic shock, 356
 - function evaluation, preoperative, 422-423
 - shock lung syndrome, 423-426
- Lupus nephropathy in pregnancy, 307-308, 310-322
 - antinuclear antibodies in, 319
 - clinical outcome of, 312-318
 - complement levels in, 319
 - corticosteroids in, 319-321

- dialysis in, 321
- diffuse proliferative, 312
- focal proliferative, 311-312
- immunosuppressive drugs in, 320
- interstitial, 312
- management of, 318-321
- membranous, 312
- mesangial, 312
- pathophysiology of, 311-312
- plasmapheresis in, 321
- Luteinizing hormone**
 - and estrogen production in, 619
 - releasing hormone secretion, 620
 - secretion in sleep, 574
 - serum levels of
 - in malnutrition, 622
 - in obesity, 647, 650-651
 - weight loss affecting, 634-636
- Lymph drainage from vulva**, 204-207
- Lymphokines**, in malignancies, 855-856
- Magnesium levels**, in cancer patients, 417
- Magnesium sulfate infusions**
 - in fetal distress, 778
 - in preeclampsia, 285
- Malnutrition**
 - adrenal hormones in, 624-625
 - in eating disorders. *See* Eating disorders
 - growth hormone levels in, 616-617
 - pancreatic hormones in, 629-630
 - and pubertal development, 575
 - steroid hormone levels in, 622-623
 - thyroid hormones in, 617-618
- Malpractice**, and cesarean births, 693-694
- MAST suit**, in hemorrhagic shock, 383
- Meig's syndrome**, 842
- Menarche**
 - and body fat, 621, 633
 - onset affected by body weight, 575
 - physical activity affecting, 577
- Menstrual cycle**, steroid hormone secretion in, 620
- Menstrual dysfunction**. *See* Amenorrhea
- Metabolism**
 - calcium, estrogen affecting, 674
 - fetal
 - of glucose, 476-478
 - insulin affecting, 480
 - of lactate, 478-479
 - hormonal, body weight affecting, 580-585, 615-630
 - neonatal, of glucose, 481-483
 - placental, of glucose, 474-476
 - in pregnancy, 457-462
 - in diabetes, 462-471
- Metaminol**
 - in hemorrhagic shock, 385
 - in septic shock, 360
- Metoclopramide**, before cesarean section, 725
- Metronidazole**, in pelvic inflammatory disease, 410
- Mezlocillin**, in infection after cesarean section, 703
- Microangiopathy**
 - diabetic, 536-539
 - and thrombotic syndrome, 103
 - compared to preeclampsia-eclampsia, 104-105
- Monitoring**
 - fetal
 - in diabetic pregnancy, 516-525
 - in nephropathy, 532
 - heart rate in, 748-750, 772-774
 - and infection from internal monitors, 699
 - scalp sampling in, 750, 773-775
 - of glucose levels in diabetic pregnancy, 499-500
 - in gestational diabetes, 510-511
- Monoclonal antibodies**
 - in studies of ovarian cancer, 853-854
 - in therapy of ovarian cancer, 858
- Morphine**, epidural, after cesarean section, 733
- Moxalactam**
 - in infection after cesarean section, 703
 - in pelvic inflammatory disease, 411
- Multiple gestation**
 - cesarean section in, 755
 - fetal death syndrome in, 29-30
- Muscle relaxants**, anesthetic emergencies from, 398-399
- Myo-inositol depletion**, in hyperglycemia, 537
- Naloxone**, effects in obesity, 653
- Nephropathy**, diabetic, in pregnancy, 308, 527-534
- Neurotransmitter activity**
 - in eating disorders, 593, 600
 - in obesity, 653-654
- Newborn**
 - glucose metabolism in, 481-483
 - herpes genitalis in, 157-158
 - transient thrombocytopenia in, 85-86, 92-93
- Nitroprusside therapy**, in hemorrhagic shock, 386
- Nuclear magnetic resonance studies**, renal, post-partum, 302
- Nutrition**
 - in acute renal failure in pregnancy, 294
 - calcium requirements in, 674
 - for cancer patients, 416
 - and dietary control of weight related to infertility, 632-642
 - dietary factors in athletic amenorrhea, 665-666
 - disorders of. *See* Malnutrition
 - in gestational diabetes, 511
 - and sociocultural influences on dieting, 599-600
 - total parenteral
 - in anorexia nervosa, 604-605
 - in cancer, 419-420

Obesity

- adrenal hormones in, 624
- amenorrhea in, 621
- androgen levels in, 648-650
- anovulation in, 655-658
- and diabetes, 629
- endocrine function in, 615
- endorphins in, 653
- estrogen levels in, 646-648
- fear of
 - in anorexia nervosa, 601
 - in bulimia, 606-607
- genetic transmission of, 658
- and gestational diabetes, 467-470
- glucose metabolism in, 628-629
- gonadotropin levels in, 585, 647, 650-651
- growth hormone levels in, 626
- hormonal abnormalities in, 646-655
- hyperthecosis in, 655-656
- infertility in, 656
- insulin levels in, 651-653
- neurotransmitters in, 653-654
- pancreatic hormones in, 628-629
- and postoperative venous thrombosis, 436
- and postoperative wound infections, 700
- and pregnancy outcome, 658
- prolactin levels in, 651, 653
- reproductive function in, 645-660
 - in males, 654-655
- steroid hormone secretion in, 621-622
- thyroid hormones, in 617
- Oligomenorrhea in athletes, 664-669
- Orciprenaline, in fetal distress, 774-775
- Osmolality of plasma
 - formula for calculation of, 425
 - in pregnancy, 263
- Osteopenia, premenopausal, 670-679
- Ovarian vessels
 - ligation of, in hemorrhage, 387-388
 - postpartum venous thrombosis, 116
- Ovariectomy, in ectopic pregnancy, 370
- Ovaries
 - polycystic disease of. *See* Polycystic ovarian disease
 - torsion of, 375-376
 - tumors of, 785-871
 - chemotherapy in, 807-810, 820, 847-848
 - high-dose, 850
 - intraperitoneal route for, 849-850
 - investigational drugs in, 848-849
 - choriocarcinoma, nongestational, 794, 826-827
 - clear-cell, 791
 - diagnosis of, 795-796
 - dysgerminomas, 793, 824-825
 - embryonal carcinoma, 794, 826
 - endodermal sinus tumor, 793, 825
 - endometrioid, 788
 - epidemiology of, 796-798
 - epithelial, 789
 - benign, 789
 - borderline, 789-790
 - invasive, 790-792
 - fibroma, 842
 - germ-cell, 793-794, 824-834
 - clinical features of, 827-828
 - diagnosis of, 829
 - mixed, 794, 827
 - operative findings in, 828-829
 - pathology of, 829
 - postoperative management in, 830-834
 - surgery in, 829-830
 - granulosa cell, 792, 839-841
 - gynandroblastomas, 844-845
 - hereditary factors in, 798
 - histogenic classification of, 787-794
 - histologic grading of, 794-795
 - and human tumor stem-cell assay, 850-851
 - imaging techniques in, 821
 - immature teratomas, 794, 825-826
 - immune response mechanisms in, 854-856
 - immunoscintigraphy in, 860-861
 - immunotherapy in, 856-857, 861-867
 - interferon therapy in, 857, 865-867
 - intraperitoneal therapy in, 849-850
 - lectin-activated autologous lymphocytes in, 858
 - metastasis of, 800
 - monoclonal antibodies in, 853-854
 - therapeutic use of, 858
 - mucinous, 789
 - in Peutz-Jeghers syndrome, 792, 798, 845
 - polembryoma, 794, 827
 - radiation therapy in, 810-813, 850
 - review questions on, 873
 - sclerosing stromal cell tumors, 842
 - second-look laparotomy in, 816-820
 - results of, 818-819
 - technique of, 817-818
 - timing of, 817
 - serous, 789
 - Sertoli-Leydig cell, 792, 842-844
 - sex cord-stromal, 792-793, 839-845
 - staging system for, 796
 - surgery in, 800-805
 - patient preparation in, 801
 - technique of, 802-805
 - thecomas, 792, 841
 - therapy with modified tumor cells, 858
 - third-look laparotomy in, 820
 - tumor markers in, 821, 828, 858-860
 - viral oncolysate preparations in, 858, 865
 - wedge resection for ovulation induction in obesity, 657
 - weight changes affecting, 618-623
- Ovulation induction
 - in athletic amenorrhea, 668
 - in obesity, 656-658
 - in slender infertile women, 642

CUMULATIVE INDEX

- Oxygen
 placental consumption of, 475
 therapy in hemorrhagic shock, 383
- Oxygenation
 in anesthesia for cesarean section, 725, 728
 and fetal distress, 772
- Oxytocin, in trial of labor after prior cesarean, 737-738
- Pain, in torsion of adnexa, 378
- Pancreas, development in fetus, 479
- Pancreatic hormones, weight changes affecting, 627-630
- Papillomavirus, and condyloma acuminatum, 142-148
- Parity, and ovarian cancer risk, 797
- Pelvic inflammatory disease, 405-412
 antibiotics in, 408-412
 in ambulatory treatment, 409
 clinical trials of, 408
 in inpatient treatment, 409-410
 anticipated pathogens in, 406
 differential diagnosis of, 379
 and ectopic pregnancy, 365
 staging of, 407
- Pelvic vein thrombophlebitis, septic, in pregnancy, 115-116
- Penicillin, in infection after cesarean section, 703
- Pentoxifylline, affecting cells, 538
- Perfusion scanning, in pulmonary embolism, 111
- Peritonitis, in cancer patients, 427-428
- Peutz-Jeghers syndrome, ovarian tumors in, 792, 798, 845
- Phlebography, in thrombosis of deep veins, 438
- Phosphorus levels, in cancer patients, 416
- Photocoagulation, in diabetic retinopathy, 540, 544-545, 547-548
- Physical activity. *See* Exercise
- Piperacillin, in infection after cesarean section, 703
- Placenta
 abruption in coagulopathy, 15-22
 in diabetic pregnancies, 463-465
 glucose metabolism in, 474-476
 lactate production in, 475
 lesions produced by endotoxin, 50
 metabolic role of, 457, 461-462
 oxygen consumption in, 475
- Placental lactogen, 461
 in test of fetal status, 517
- Plasmapheresis, in lupus nephropathy in pregnancy, 321
- Plasmin
 α_2 -antiplasmin, 12
 deficiency in pregnancy, 67
- Plasminogen, 12
- Platelets
 in abruptio placentae, 16
 adhesion of, 3-4
 antibodies to, assays for, 87-91
 antigens and surface receptors of, 86-87
 factor 4, 4
 oral contraceptives affecting, 75-76
 plug formation in hemostasis, 3
 in preeclampsia, 38
 in thrombocytopenic purpura
 immunologic, 84-99
 thrombotic, 101-105
- Plethysmography, impedance, 109-110
- Pneumonitis, aspiration, during labor, 724-725
- Podophyllin, in condyloma acuminatum, 147
- Polycystic ovarian disease
 androgen levels in, 649
 endorphins in, 653
 insulin levels in, 652
 LH/FSH ratio in, 647, 650
 obesity in, 621, 647
- Polyembryoma of ovary, 794, 827
- Potassium levels
 in acute renal failure, 294
 in cancer patients, 416, 417
- Prader-Willi syndrome, obesity in, 621, 655
- Preeclampsia, 279-285
 acute renal failure in, 291
 coagulation system in, 37-44
 compared to thrombotic microangiopathic syndrome, 104-105
 and histologic changes in kidney, 281
 management of, 284-285
 proteinuria in, 282-283
 renal hemodynamics in, 281-282
 renin-angiotensin-aldosterone system in, 283-284
 thrombocytopenia in, 98
 water and electrolyte balance in, 282
- Pregnancy
 after renal transplantation, 317, 339-349
 coagulation in, 16, 49-50
 coagulopathy in. *See* Coagulopathy in pregnancy
 condyloma acuminatum in, 147
 diabetes in, 455-567. *See also* Diabetes mellitus
 ectopic, 365-374. *See also* Ectopic pregnancy
 fatty liver in, acute, 306
 hemolytic uremic syndrome in, 101-105
 herpes genitalis in, 157-158
 lupus nephropathy in, 307-308, 310-322
 metabolism in, 457-462
 in diabetes, 462-471
 in obesity, 658
 renal morphology in, 249-253
 renal physiology in, 257-264
 thrombocytopenic purpura in
 immunologic, 84-99
 thrombotic, 101-105, 307
 thromboembolic disease in, 107-116
 urinary tract in. *See* Urinary tract, in pregnancy

- Prekallikrein
 activation of, 7
 deficiency in pregnancy, 62
- Prematurity
 cesarean section in, 752-758
 fetal distress in, 776-777
 in renal transplant patients, 342
- Prenatal tests, and fetal outcome in diabetic pregnancy, 491-492, 516-525
- Progesterone, 619
 serum levels affected by weight loss, 623
 as therapy in vulvar lichen sclerosis, 184-185
- Prolactin secretion, 620
 in obesity, 622, 651, 653
 weight loss affecting, 623
- Prostacyclin, oral contraceptives affecting, 75
- Prostaglandins, in endotoxic shock, 357
- Protein
 dietary, metabolic responses to, 628
 metabolism in pregnancy, 459-461
- Protein C, activated, 11-12
- Proteinuria in pregnancy, 299-300
 in lupus nephropathy, 316
 postpartum evaluation of, 304-305
 and preeclampsia, 282-283
 in renal transplant patients, 343
- Prothrombin, 5
 abnormalities in pregnancy, 66-67
- Pruritus vulvae
 compared to vulvodinia, 123-133
 in hyperplastic dystrophy, 179-180
- Psychologic aspects
 of amenorrhea in athletes, 665
 of anorexia nervosa, 594-595, 603
 of bulimia, 608-609
 of cesarean section, 767
 of vulvar itching or burning, 130
- Puberty
 bone mineral density in, 673
 onset related to body weight, 573-578
 physiology of, 633-634
 precocious, and luteinizing hormone secretion during sleep, 574
 steroid hormone secretion in, 620-621
- Puerperium, renal function evaluation in, 298-308
- Purpura, thrombocytopenic, in pregnancy
 immunologic, 84-99
 thrombotic, 101-105, 307
- Pyelography, intravenous
 in postpartum period, 301
 in renal calculi in pregnancy, 327-328
- Pyelonephritis in pregnancy, 270-276
 postpartum evaluation in, 303
 recurrent, 276
 treatment of, 276
- Radiation therapy, in ovarian cancer, 806-809, 846
- Radioisotope scans
 in pulmonary embolism, 438
 in renal calculi in pregnancy, 328
- Radiology
 in pulmonary embolism, 437-438
 in renal calculi in pregnancy, 327
 in septic shock, 358
- Ranitidine, before cesarean section, 725
- Reflux, vesicoureteral, in pregnancy, 254
- Respiratory failure, in cancer patients, 418
- Retinopathy, diabetic, 539-546
 in pregnancy, 546-549
- Rh immunoglobulin, in ectopic pregnancy, 373
- Ringworm of vulva, 129
- Ritodrine, in fetal distress, 778
- Runners, amenorrhea in, 664
- Saline amnioinfusion, in fetal distress, 778
- Salpingectomy, in ectopic pregnancy, 369
- Salpingostomy, in ectopic pregnancy, 370-371
- Salpingotomy, in ectopic pregnancy, 371
- Scalp sampling, fetal, 750, 773-775
- Screening for gestational diabetes, 467, 508-509
- Sellick's maneuver, before tracheal intubation, 395, 396
- Sepsis, and coagulation, 46-51
- Septic shock, 355-363
- Sertoli-Leydig cell tumors of ovary, 792, 842-844
- Sex steroid metabolism, weight changes affecting, 618-623
- Sexually transmitted diseases
 condyloma acuminatum, 142-148
 herpes genitalis, 152-161
- Shock
 hemorrhagic, 381-389
 blood transfusions in, 385
 control of hemorrhage in, 387-389
 crystalloid solutions in, 384
 drug therapy in, 385-386
 fluid replacement in, 383-384
 MAST suit in, 383
 oxygen therapy in, 383
 pathophysiology of, 381-382
 septic, 355-363
 clinical features of, 358
 and coagulation, 46-51
 laboratory studies in, 358-359
 medical treatment of, 357, 359-361
 pathophysiology of, 355-358
 steroid/antibiotic therapy in, 357
 surgery in, 361
- Shock lung syndrome, 423-426
- Skeletal mass, premenopausal, weight affecting, 670-679
- Smoking, and oral contraceptive use, 80
- Sociocultural influences on dieting, 599-600
- Sociocultural status, and postpartum infection, 699-700

- Sodium levels
 in acute renal failure, 294
 in cancer patients, 416, 417
 postpartum, 299
 in pregnancy, 263
 in preeclampsia, 282
- Somatomammotropin, chorionic, 461
- Somatomedins, 625
- Somatostatin, 626, 628
- Spermatogenesis, obesity affecting, 654-655
- Splenectomy, in immunologic thrombocytopenic purpura, 93
- Starvation
 adrenal hormones in, 624-625
 compared to anorexia nervosa, 589, 592, 601
 growth hormone levels in, 616-617
 pancreatic hormones in, 629-630
 steroid hormone levels in, 622-623
 thyroid hormones in, 617-618
- Steroid hormones, weight changes affecting, 618-623
- Streptokinase, in postoperative venous thromboembolism, 441-442
- Stress, and amenorrhea in athletes, 665
- Subarachnoid block, in cesarean section, 731-732
- Succinylcholine, anesthetic emergencies from, 398-399
- Surgery
 anesthetic emergencies in, 391-402
 cesarean. *See* Cesarean section
 complications in cancer patients, 420-429
 control of hemorrhage in, 387
 in ectopic pregnancy, 369-373
 in ovarian tumors, 800-805
 in germ-cell tumors, 829-830
 and postoperative venous thromboembolism, 432-445
- Tachycardia, in septic shock, 358
- Teratogenic effects of diabetic pregnancies, 486-494
- Teratoma, immature, of ovary, 794, 825-826
- Testosterone
 metabolism affected by weight loss, 622-623
 production in women, 619
 in anorexia nervosa, 622
 in obesity, 621, 648-649
 topical, in vulvar lichen sclerosus, 184
- Thecomas, 792, 841
- Thiopental, in cesarean section, 729
- Thrombasthenia, Glanzmann, 4
- Thrombectomy, in venous thrombosis, 442
- Thrombin
 antithrombin III, 10-11
 formation of, 7-9
- Thrombocytopenia, in pyelonephritis, 273
- Thrombocytopenic purpura in pregnancy
 immunologic, 84-99
 and assays for anti-platelet antibodies, 87-91
 delivery route in, 96-98
 immune complexes in, 91
 maternal therapy in, 93-94
 platelet-specific antigens and surface receptors in, 86-87
 and transient neonatal thrombocytopenia, 85-86, 92-93
 autoimmune, 85
 isoimmune, 85-86
 management of, 97-98
 prediction of, 94-96
 thrombotic, 101-105, 307
- Thromboembolism
 and oral contraceptive use, 73-81
 postoperative, 432-445
 coagulation factors in, 434-435
 diagnosis of, 436-439
 incidence of, 432-433
 pathogenesis of, 433-435
 prevention of, 442-445
 risk factors for, 435-436
 treatment of, 439-442
 in pregnancy, 107-116
 diagnosis of, 107-111
 treatment of, 111-116
- β -Thromboglobulin, 4
- Thrombophlebitis, septic pelvic, 361
- Thrombotic microangiopathic syndrome in pregnancy, 101-105
- Thrombotic thrombocytopenic purpura in pregnancy, 101-105, 307
- Thromboxane A_2 , oral contraceptives affecting, 75
- Thyroid hormones
 secretion and metabolism of, 616-617
 serum levels in eating disorders, 592
 weight changes affecting, 616-618
 in obesity, 617
 in starvation or malnutrition, 617-618, 624
- Tinea infections of vulva, 129
- Tobramycin, in pelvic inflammatory disease, 410
- Tocolytic agents, in fetal distress, 777-778
- Torsion, 375-380
 course of, 377-378
 diagnosis of, 378
 differential diagnosis of, 378-379
 ovarian, 375-376
 treatment of, 379
 tubal, 376-377
- Toxemia of pregnancy, and postpartum evaluation, 304
- Tracheal intubation
 complications from, 393-394
 and Sellick's maneuver, 395, 396
- Tracheostomy, in anesthetic emergencies, 394
- Transfusions. *See* Blood transfusions
- Trichloroacetic acid, in condyloma acuminatum, 147
- Tumors. *See* Cancer, gynecologic

CUMULATIVE INDEX

- Twin gestation
 cesarean section in, 755
 fetal death syndrome in, 29-30
- Ultrasonography
 in diabetic pregnancies, 491, 492
 in ectopic pregnancy, 367-368
 of kidney, postpartum, 301
 in renal calculi in pregnancy, 328
 in thromboembolic disease in pregnancy, 110
 in thrombosis of deep veins, 438
- Urea clearance, in pregnancy, 259-260
- Ureters
 morphologic changes in pregnancy, 245-253
 obstruction in pregnancy, renal failure from, 291-292
 postpartum dilatation of, 298
- Uric acid levels, in pregnancy, 261
- Urinary tract
 infections of, vulvar burning in, 129
 in pregnancy
 acute renal failure in, 288-296
 assessment and treatment of renal disease, 279-287
 calculi in, 271, 324-337
 chronic renal disease in, 285-287
 infections in, 266-277
 and postpartum evaluation, 303
 in renal transplant patients, 341
 lupus nephropathy in, 307-308, 310-322
 morphologic changes in, 249-255
 postpartum evaluation of renal function, 298-308
 renal physiology in, 257-264
- Urine culture techniques, 267
- Urokinase, in postoperative venous thromboembolism, 441-442
- Uterine arteries, ligation of, in hemorrhage, 388
- Uterus
 contraction stress tests, fetal heart rate in, 517-518, 522-523
 in pregnancy, glucose supply to, 474
 rupture in vaginal birth after cesarean section, 736
- Vaccines
 in condyloma acuminatum, 148
 in herpes simplex prevention, 158, 164-176
 in immunotherapy of ovarian cancer, 856-857, 865
- Vaginal examinations, number of, and postpartum infections, 699
- Vaginitis
 atrophic, vulva in, 128
 infectious, vulvar burning in, 126-127
- Varicose veins, and postoperative venous thrombosis, 436
- Vascular abnormalities in diabetes, 536-539
- Vasopressin secretion in pregnancy, 263-264, 282
- Venography, in thrombosis diagnosis, 109
- Ventilation emergencies in anesthesia, 393-395
- Ventilation scanning, in pulmonary embolism, 111
- Vertex delivery, preterm, cesarean section in, 754-755
- Vesicoureteral reflux in pregnancy, 254
- Vestibule of vulva, 134-141
- Vidarabine, in herpes genitalis, 161
- Virus infections
 condyloma acuminatum, 142-148
 herpes genitalis, 152-161
- Vitamin K, and coagulation, 5-6
- Vitrectomy, in diabetic retinopathy, 546
- Vomiting
 and aspiration of gastric contents in anesthesia, 395-396
 and aspiration pneumonitis during labor, 724-725
 self-induced, in bulimia, 602, 607, 609
- Von Willebrand factor, 4, 7
- Von Willebrand syndrome, 4, 7
 in pregnancy, 55-57
 treatment of, 57
- Vulva
 carbon dioxide laser therapy in diseases of, 220-228
 in condyloma acuminatum, 223-226
 in dystrophies, 226-227
 in herpes genitalis, 227-228
 in squamous cell carcinoma *in situ*, 221-223
 carcinoma of
in situ
 carbon dioxide laser in, 221-223
 itching or burning in, 129
 and lichen sclerosus, 183-184
 relation to condyloma acuminatum, 146
 superficially invasive, 188-194
 depth of invasion in, 189-192
 follow-up of, 194
 growth pattern of, 192-193
 tumor differentiation in, 192
 tumor volume in, 193-194
 vascular space involvement in, 192
 vulvectomy and inguinal lymphadenectomy in, 196-202
 in vestibule, 140
 condyloma acuminatum of, 142-148
 carbon dioxide laser in, 223-226
 discomfort in, 123-133
 differential diagnosis of, 126-130
 itching versus burning in, 124-126
 management of, 130-133
 dystrophy of, 178-185
 carbon dioxide laser in, 226-227
 hyperplastic, 179-181
 herpes genitalis, 152-161
 carbon dioxide laser in, 227-228

CUMULATIVE INDEX

- vaccines in, 158, 164-176
- inoperable tumors of, 209
- lichen sclerosis, 181-185
 - carbon dioxide laser in, 226
- lymph drainage from, 204-207
- lymphadenectomy in squamous cell carcinoma, 207-209
- reconstruction of, 211-219
 - gracilis myocutaneous flap in, 212-213
 - split-thickness skin graft in, 212
 - tensor fascia lata flap in, 213-218
- review questions on, 230
- vestibule of, 134-141
 - adenitis of, 129, 134-137
 - carbon dioxide laser in, 227
 - carcinoma of, 140
 - trauma of, 138
 - tumors in, 139-141
- Vulvodinia, compared with pruritus vulvae, 123-133
- Warts, in condyloma acuminatum, 142-148
- Weight, 569-581
 - and bone mass in premenopausal women, 670-679
 - changes in, and endocrine function, 615-630
 - adrenal hormones, 623-625
 - growth hormone and somatomedins, 625-627
 - ovaries and sex steroids, 618-623
 - pancreatic hormones, 627-630
 - thyroid hormones, 616-618
 - control practices related to infertility, 632-642
 - and eating disorders. *See* Eating disorders
 - and extraglandular estrogen production, 580-585
 - gain of, physiologic changes in, 640-641. *See also* Obesity
 - and gestational diabetes, 467-470
 - ideal, calculation of, 637-638
 - and initiation of puberty, 573-578
 - loss of
 - and amenorrhea in athletes, 664-665
 - lipoprotein lipase activity in, 659
 - in obesity, ovulatory function after, 656-657
 - recommendations for, 658-659
 - and premenopausal osteopenia in thin patients, 570-579
 - and reproductive function in obesity, 645-660
 - in males, 654-655
 - review questions on, 681



AUTHOR INDEX

- Ayers, Jonathan W. T., 670
 Baker, Elizabeth R., 573
 Barber, Hugh R. K., 414
 Bassell, Gerard M., 722
 Bates, G. William, 569, 632
 Beller, Fritz K., 46
 Beydoun, Samir N., 249
 Biggs, Ronald S., 697
 Bonnar, John, 432
 Brandt, John T., 3
 Burkett, Gene, 310
 Caldwell, David C., 53
 Carpenter, Marshall W., 507
 Cavanagh, Denis, 353, 355, 381
 Copel, Joshua A., 24
 Copeland, Larry J., 816
 Coustan, Donald R., 507
 Davison, J. M., 257
 DeCherney, Alan H., 365
 Delclos, Luis, 806
 DiSaia, Philip, 196
 Edwards, Creighton L., 800, 806
 Faro, Sebastian, 152
 Flamm, Bruce L., 735
 Freedman, Ralph S., 853
 Friedman, Chad I., 645
 Friedrich, Eduard G., Jr., 121, 134, 178, 220
 Gabbe, Steven G., 455, 496, 528
 Gershenson, David M., 824
 Gibbs, Ronald S., 697
 Golde, Steven, 516
 Goldsmith, Jonathan C., 53
 Hankins, Gary D. V., 266
 Hay, William W., Jr., 473
 Henley, Karen M., 711
 Hibbard, Lester T., 711
 Hobbins, John C., 24
 Hollingsworth, Dorothy Reycroft, 457
 Horowitz, Eliot, 324
 Iams, Jay D., 745
 Iversen, Torbjørn, 204
 Jaffe, David J., 298
 Johnson, William G., 598
 Jolles, Christopher J., 787
 Jones, Ervin E., 365
 Julian, Peter J., 375
 Kaplan, Alan L., 211
 Kaufman, Raymond H., 121, 152, 220
 Kavanagh, John J., 846
 Killam, Allen, 32
 Kim, Moon H., 645
 Kit, Malon, 164
 Kit, Saul, 164
 Knuppel, Robert A., 288
 Kwaan, Hau C., 101
 Landon, Mark B., 496
 Lau, R. Jane, 84, 339
 Lynch, Peter J., 142
 Marsden, Donald E., 381
 McKay, Marilynne, 123
 Mead, Philip B., 405
 Meeks, G. Rodney, 580
 Mennuti, Michael T., 486
 Montenegro, Raul, 288
 Nageotte, Michael P., 770
 Nesler, Cheryl L., 528, 536
 Nichols, David H., 375
 Notelovitz, Morris, 73
 O'Brien, William F., 288
 Paul, Richard H., 752
 Petitti, Diana B., 763
 Philipson, Elliot H., 691
 Platt, Lawrence, 516
 Quilligan, Edward J., 689
 Rao, Papineni S., 355
 Reiss, Rosemary, 745
 Roberts, William S., 355
 Robertson, Euan G., 247, 279
 Romero, Roberto, 24
 Rosen, Mortimer G., 691
 Rote, Neal S., 84
 Saul, Patton B., 839
 Schlundt, David G., 598
 Schmidt, Joseph D., 324
 Schwartz, Stanley S., 528, 536
 Scott, James R., 339
 Shangold, Mona M., 664
 Sher, Geoffrey, 15
 Sinclair, Stephen H., 528, 536
 Smith, Bradley E., 391
 Sparks, John W., 473
 Statland, Bernard E., 15
 Steel, Judith M., 553
 Stringer, C. Allen, 800, 806

AUTHOR INDEX

ten Cate, Jan W., 37
Treffers, Pieter E., 37
Vaitukaitis, Judith L., 615
Warren, Michelle P., 588
Weenink, Gerhard H., 37
Weiner, Carl P., 1, 107
Westgren, Magnus, 752

Whalley, Peggy J., 266
Wharton, J. Taylor, 785, 800, 806
Whitworth, Neil S., 580
Wilkinson, Edward J., 188
Williamson, Roger A., 46
Woodruff, J. Donald, 134, 230

